Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Nault JC, Campani C, Hirsch TZ, Neumann E, Arif W, Imbeaud S, Baretti M, Ziol M, Sidali S, Roger P, Allaire M, Bouattour M, Marra F, Fresneau B, Llarch N, Peron JM, Gerolami R, Khac EN, Nahon P, Ganne-Carrié N, Caldéraro J, Beaufrère A, Paradis V, Guettier C; CAPRIH FFCD cohort; Sutton A, Yarchoan M, …

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma. Read More »

Improving risk stratification and detection of early HCC using ultrasound-based deep learning models.

Dana J, Meyer A, Paisant A, Rode A, Sartoris R, Séror O, Cassinotto C, Milot L, Grégory J, Cœur J, Lebigot J, Schembri V, Villeret F, Takeda AN, Ronot M, Vilgrain V, Baumert TF, Gallix B, Padoy N, Nahon P. JHEP Rep. 2025 Jul 5;7(10):101510. Background & aims: Hepatocellular carcinoma (HCC) surveillance programs are suboptimal. …

Improving risk stratification and detection of early HCC using ultrasound-based deep learning models. Read More »

Associations between fruit and vegetable consumption and HCC occurrence in patients with cirrhosis.

Manneville F, Zouakia Z, Donneger S, Fezeu LK, Bellicha A, Nahon P, Touvier M, Ganne-Carrié N, Julia C. JHEP Rep. 2025 Feb 13;7(5):101355 Background & aims: Prospective studies are needed to increase knowledge of fruit and vegetable consumption effects on hepatocellular carcinoma (HCC) risk. This study aimed to investigate the association between fruit and vegetable …

Associations between fruit and vegetable consumption and HCC occurrence in patients with cirrhosis. Read More »

Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma.

Blaise L, Ziol M, Campani C, Ganne-Carrie N, Nahon P, Nkontchou G, Zucman-Rossi J, Del Pozo L, Barget N, Boros C, Desjonqueres E, Demory A, Grando V, Pescatori L, Seror O, Sutter O, Nault JC. JHEP Rep. 2025 Apr 22;7(9):101430. Background & aims: We aimed to assess the safety and diagnostic/prognostic value of tumor and …

Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma. Read More »

The “A-B-C” Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab.

Campani C, Galvanin C, Shim JH, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Paradis V, Calderaro J, Ziol M, Beaufrère A, Sayadi A, Amaddeo G, Allaire M, Olivier-Hourmand I, Metivier C, Rondini E, Ronot M, Ntandja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande …

The “A-B-C” Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab. Read More »

Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.

Trépo E, Zucman-Rossi J, Nault JC. Nat Rev Gastroenterol Hepatol. 2026 Feb 12 Steatotic liver diseases, encompassing metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease, affect nearly one-third of the global population and are a leading cause of cirrhosis and hepatocellular carcinoma. The substantial interindividual variation in disease progression indicates important genetic contributions beyond …

Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis. Read More »

[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study

Nault JC, Boubaya M, Wartski M, Dohan A, Pol S, Pop G, Soussan M, Sutter O, Costentin C, Roux J, Sengel C, Lequoy M, Montravers F, Menu Y, Pageaux GP, Goulart DM, Guiu B, Luciani A, Nahon P, Dioguardi Burgio M, Wagner M, Maksud P, Mulé S, Allaire M, Sidali S, Coilly A, Besson FL, …

[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study Read More »

Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis

Nahon P, Lusivika-Nzinga C, Merle P, Zoulim F, Decaens T, Ganne-Carrié N, Pageaux GP, Leroy V, Alric L, Bronowicki JP, Bourlière M, Gournay J, Tran A, Pol S, Mathurin P, Loustaud-Ratti V, Métivier S, De Ledinghen V, Abergel A, Thabut D, D’Alteroche L, Bouattour M, Asselah T, Ouzan D, Cales P, Chazouillères O, Gelu-Simeon M, …

Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis Read More »

Differences between hepatocellular carcinoma caused by alcohol and other aetiologies

Ganne-Carrié N, Nahon P.J Hepatol. 2024 Dec 20:S0168-8278(24)02817-4. doi: 10.1016/j.jhep.2024.12.030. Online ahead of print. Abstract Alcohol-related liver disease is the third leading cause of hepatocellular carcinoma worldwide and the leading cause in Europe. Additionally, the recent definition of metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD) will enrich this population with a more …

Differences between hepatocellular carcinoma caused by alcohol and other aetiologies Read More »

Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study

Nault JC, Sritharan N, Verset G, Borbath I, Lequoy M, Allaire M, Regnault H, Colle I, Orlent H, Sinapi I, Moreno C, Larrey E, Sidali S, Hollande C, Amaddeo G, Pol S, Nahon P, Ganne-Carrié N, Levy V, Bloch-Queyrat C; Paris Liver Cancer Group; Trepo E, Bouattour M.JHEP Rep. 2024 Aug 22;6(11):101192. doi: 10.1016/j.jhepr.2024.101192.  Abstract …

Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study Read More »